RxDoctor Payments Data

Stephanie Farmer, PA

Physician Assistant · Danielson, CTNPI 1295202927

Payments from drug & device makers

$5,558in general payments, 2019–2025

Across 286 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$639
  • GSK$623
  • Lilly USA, LLC$397
  • Boehringer Ingelheim$339
  • Otsuka America Pharmaceutical, Inc.$297
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,43298%
  • Education$1252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,558 in reported general payments places this provider in the 90th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$22,010
Medicare patients
70
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$93,317
JardianceEmpagliflozin31$41,265
EliquisApixaban26$28,823
Albuterol Sulfate HfaAlbuterol Sulfate59$1,680
Atorvastatin Calcium187$1,413
Gabapentin63$1,251
Famotidine34$1,099
Duloxetine Hcl20$864
Levothyroxine Sodium113$740
Pantoprazole Sodium70$680
Omeprazole49$600
Ipratropium Bromide24$568
Ezetimibe34$567
Lisinopril94$541
Metformin Hcl ErMetformin Hcl40$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$623$93,31760 claims
Boehringer IngelheimJardiance$339$41,26531 claims
PfizerEliquis$178$28,82326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Danielson

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →